Perils of evidence-based medicine

Perspectives in Biology and Medicine

Volumn 53, Issue 1, 2010, Pages 106-120

  Williams, Ben A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; HUMAN; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS, PHASE III AS TOPIC; DATA INTERPRETATION, STATISTICAL; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 77950141742     PISSN: 00315982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bairati, I., et al. 2006. Antioxidant vitamins supplementation and mortality: A randomized trial in head and neck cancer patients. Int J Cancer 119:2221-24.
2. Bakan, D. 1966. The test of significance in psychological research. Psychol Bull 66:423-37.
3. Bamber, D. 1975. The area above the ordinal dominance graph and area below the receiver operating characteristic graph. J Math Psychol 12:387-415.
4. Bluhm, R. 2005. From hierarchy to network: A richer view of evidence for evidence-based medicine. Perspect Biol Med 48(4):535-47.
5. Borgerson, K. 2009. Valuing evidence: Bias and the evidence hierarchy of evidence-based medicine. Perspect Biol Med 52(2):218-33.
6. Cairncross, G., et al. 2006. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24(18):2707-14.
7. Cartwright, N. 2007. Are RCTs the gold standard? Biosocieties 2(2): 11-20.
8. Chamberlain, M. D., and K. A. Jaeckle. 2001. Medical Research Council adjuvant trial in high-grade gliomas. J Clin Oncol 19(19):3997-98.
9. Curran, W. J., et al. 1993. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Canc Inst 85:704-10.
10. Flaker, G. C., et al. 1992. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation: The stroke prevention in atrial fibrillation investigators. J Am Coll Cardiol 20(3):527-32.
11. Goldenberg, M. J. 2009. Iconoclast or creed? Objectivism, pragmatism, and the hierarchy of evidence. Perspect Biol Med 52(2):168-87.
12. Grossman, J., and F. J. Mackenzie. 2005. The randomized controlled trial: Gold standard or merely standard? Perspect Biol Med 48(4):516-34.
13. Halpern, S. D., J. H. Karlawish, and J. A. Berlin. 2002. The continuing unethical conduct of underpowered clinical trials. JAMA 288:358-62.
14. Hegi, M. E., et al. 2005. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997-1003.
15. Killeen, P. R. 2005. An alternative to null hypothesis significance tests. Psychol Sci 16:345-53.
16. Lafuente-Lafuente, C., et al. 2006. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: A systematic review of randomized controlled trials. Arch Intern Med 166(7):719-28.
17. Li, Y., et al. 2002. The use of frailty hazard models for unrecognized heterogeneity that interacts with treatment: Considerations of efficiency and power. Biometrics 58:232-36.
18. Medical Research Council Brain Tumour Working Party. 2001. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial. J Clin Oncol 19(2):509-18.
19. Meyer, F., et al. 2008. Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: A randomized trial among head and neck cancer patients. Int. J. Cancer 122:1679-83.
20. Prados, M. D., et al. 2004. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: Final report of RTOG 9404. Int J Radiat Oncol Biol Phys 58(4):1147-52.
21. Rozeboom, W. 1960. The fallacy of the null-hypothesis significance test. Psychol Bull 57: 416-28.
22. Scott, C. B., et al. 1998. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40(1):51-55.
23. Selker, R. G., et al. 2002. The Brain Tumor Cooperative Group NIH Trial 87-01: A randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51:355-57.
24. Stupp, R., et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-96.
25. Van den Bent, J. J., et al. 2006. Adjuvant procarbazine, lomustine, and vincristine improve progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer Phase III trial. J Clin Oncol 24(18):2715-22.
26. Videtic, G. M. M., et al. 1999. Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas. Intl J Rad Onc Biol Phys 45(4):687-92.
27. Wong, E. T., et al. 1999. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572-78.
28. Yung, W. K., et al. 2000. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5):588-93.